Vanguard Global Advisers
SUPN icon

Vanguard Global Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

Vanguard Global Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Sell
22,004
-2,890
-12% -$139K ﹤0.01% 1734
2026
Q1 		$1.29M Buy
+24,894
New +$1.27M ﹤0.01% 1484

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Vanguard Global Advisers's SUPN Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Supernus Pharmaceuticals (SUPN) stake by 12% in Q2 2026, selling an estimated $139K and leaving 22,004 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1734.

Vanguard Global Advisers first reported a position in SUPN in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.29M in Q1 2026. 329 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Vanguard Global Advisers held 22,004 shares of Supernus Pharmaceuticals worth $1.02M as of Q2 2026.
  • Vanguard Global Advisers sold 2,890 Supernus Pharmaceuticals shares in Q2 2026, an estimated $139K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1734 holding.
  • Vanguard Global Advisers first reported a position in Supernus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Supernus Pharmaceuticals position peaked at $1.29M in Q1 2026.
  • 329 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.